1 / 6

Vaccination & cochlear implants

Vaccination & cochlear implants. Meningitis risk x30 positioner cochlear anomaly. Vaccination & cochlear implants. Prevention technique AOM treatment vaccination PCV13. Pneumococcal vaccination. Pneumovax 23-valent polysaccharide vaccine FDA 1983: not <24mths

natane
Télécharger la présentation

Vaccination & cochlear implants

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vaccination & cochlear implants • Meningitis risk x30 • positioner • cochlear anomaly

  2. Vaccination & cochlear implants • Prevention • technique • AOM treatment • vaccination • PCV13

  3. Pneumococcal vaccination • Pneumovax • 23-valent polysaccharide vaccine • FDA 1983: not <24mths • Not effective for AOM (Straetemans 2004) • Prevnar • 7-valent conjugate vaccine (80% of invasive disease) • FDA 2000: invasive infection and AOM • Prevnar 13 • 6 extra serotypes (92% of invasive disease) • FDA Feb 2010

  4. Vaccination & cochlear implants • AAP recommendations 2010 • all children: 4 doses PCV13 • CI children: • complete PCV7 or PPSV23 1 dose PCV13 • ≤ 2 doses of PCV7 2 doses PCV13 • complete PCV13; >2 yrs PPSV23

  5. Vaccination & cochlear implants • AAP recommendations 2010 • all children: 4 doses PCV13 • CI children: • complete PCV7 or PPSV23 1 dose PCV13 • ≤ 2 doses of PCV7 2 doses PCV13 • complete PCV13; >2 yrs PPSV23

More Related